




PHARMACEUTICAL 2022

Y-mAbs Therapeutics Inc.
Rank 130 of 466





RealRate

PHARMACEUTICAL 2022

Y-mAbs Therapeutics Inc. Rank 130 of 466



The relative strengths and weaknesses of Y-mAbs Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Y-mAbs Therapeutics Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 50% points. The greatest weakness of Y-mAbs Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 208%, being 130% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	202,261
Cost of Goods Sold	2,304
Intangible Assets	1,663
Liabilities, Current	27,875
Liabilities, Non-Current	2,702
Other Assets	7,012
Other Compr. Net Income	1,897
Other Expenses	210
Other Liabilities	2,100
Other Net Income	60,158
Other Revenues	34,897
Property and Equipment	1,847
Research and Development	93,245
Selling, General and Administrative Expense	54,571

Output Variable	Value in 1000 USD
Assets	212,783
Liabilities	32,677
Expenses	150,330
Revenues	34,897
Stockholders Equity	180,106
Net Income	-55,275
Comprehensive Net Income	-54,326
Economic Capital Ratio	208%